Focal Segmental Glomerulosclerosis
May 20, 2025
Incyte’s ZYNYZ Approved as First-Line Treatment for Advanced Anal Cancer; Amneal Gets FDA Nod for BREKIYA for Migraines; FDA Accepts Travere’s sNDA for FILSPARI in FSGS; AbbVie’s EMRELIS Approved for Advanced NSCLC With High c-Met; Merck’s WELIREG Approved for Advanced PPGL in Patients 12+
Incyte’s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval incl...
Read More...
Sep 16, 2022
Focal Segmental Glomerulosclerosis Market: Unfolding Insights into the Future
Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options. The off-label therapies majorly include nonimmune therapies in conjunction wi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
